Leadership
Harbour BioMed Appoints Dr. Sanjay Keswani as Scientific Advisor in Neuroscience
By News Desk ·
Key takeaways
- Dr. Sanjay Keswani joins Harbour BioMed as Scientific Advisor in Neuroscience, bringing more than 25 years of neuroscience research and clinical development experience.
- Keswani most recently served as Chief Medical Officer of Neurocrine Biosciences and previously was President and CEO of ImmunoBrain.
- At Roche, Keswani led a global organization of approximately 250 professionals and advanced five molecules into Phase 3 clinical development.
Harbour BioMed appointed Dr. Sanjay Keswani as Scientific Advisor in Neuroscience, the company said in a TradingView report on November 17, 2026. Keswani brings more than 25 years of experience in neuroscience research, pharmaceutical R&D and clinical development. The appointment is not a board seat, and the announcement names no predecessor.
Keswani's Clinical Development Record
Keswani most recently served as Chief Medical Officer of Neurocrine Biosciences, where he led clinical development across neurology, psychiatry, immunology, obesity and rare endocrine diseases. Before that, he was President and CEO of ImmunoBrain, a clinical-stage biotechnology company developing therapies that use neuro-immune communication to promote brain repair in neurodegenerative disease.
He also served as Executive Vice President and Chief Medical Officer of Annexon Biosciences, where he led clinical development and oversaw multiple clinical programs, including a positive Phase 2/3 study in Guillain-Barré syndrome and four Phase 2 studies in hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis and geographic atrophy. Earlier, at Roche, he was Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare Diseases, leading a global organization of approximately 250 professionals and advancing five molecules into Phase 3 clinical development, including risdiplam for spinal muscular atrophy and faricimab for diabetic macular edema and wet age-related macular degeneration.
Keswani began his academic and clinical career at Johns Hopkins University as Assistant Professor of Neurology, and held senior R&D and clinical development positions at Bristol Myers Squibb, Eli Lilly and Amgen. He received his MBBS from St. Bartholomew's Hospital and an Honors BSc from St. Mary's Hospital, London, and is a Fellow of the Royal College of Physicians (UK).
"His extensive expertise in neuroscience research and drug development, together with his proven track record of advancing innovative therapies through clinical development, will bring valuable insights to our scientific endeavors," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
Earlier Leadership Appointments at Harbour BioMed
Harbour BioMed appointed Vivian Feng as Senior Vice President, Head of External Collaboration, based in Shanghai, PR Newswire reported on November 5, 2026. She will lead external collaboration strategy, business development and licensing across the HBM Group.
On August 27, 2026, Harbour BioMed appointed CFO Youchen Chen and Senior Vice President and Global Head of Legal Dr. Ian Y. Liu as Executive Directors, effective immediately, Aijourn reported. On August 6, 2026, the company appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise to advance therapies for obesity, metabolic diseases, liver diseases and cardiovascular disorders, PR Newswire APAC reported.
Solstice Oncology Trial Timing
Solstice Oncology, a partner of Harbour BioMed, said its Phase 2 trial of porustobart in MSS colon cancer will open in the fourth quarter of 2026, with data expected in the second half of 2027, PR Newswire reported on September 9, 2026.
Companies in this story
- Harbour Biomed · www.harbourbiomed.com